Acquisition of Radioactive products (PLUVICTO and LUTATHERA)

The Defense Health Agency (DHA), Healthcare Contracting Division Northeast (HCD-NE), on behalf for the Department of Radiology Department located at Walter Reed National Military Medical Center (WRNMMC), 8901 Wisconsin Avenue, Bethesda, MD 20889, under the statutory authority of the Federal Acquisition Regulation (FAR) 6.302-l(a) (2) (iii) (b), sole source, for the requirement for radioactive products (PLUVICTO and LUTATHERA) used for imaging patient’s disease, intends to award a Firm-Fixed Price, to Novartis Pharmaceuticals Corporation. Manufactured radioactive products (PLUVICTO and LUTATHERA) used for imaging patient’s disease must be U.S. FDA Approved.

Novartis Pharmaceuticals Corporation, (CAGE: 04520), 59 Route 10, East Hanover, NJ 07936 is the FDA Approved Manufacturer for PLUVICTO and LUTATHERA. The total cost for the Purchase Order is estimated at $578,754.32. The associated NAICS code applicable to this requirement is 325412 - Pharmaceutical Preparation Manufacturer. This notice of intent to award a competitive Purchase Order is not a request for competitive proposals. There will be no Request for Quote (RFQ) or Solicitation available for competition.

Phone calls will not be accepted. This notice is not a request for competitive quotes; however, the government will consider responses to this notice within five (5) days of this posting. Interested parties, may express their interest, and provide a capabilities statement NLT January 11, 2026, at 7:00 AM EST. The point of contact for this action is Malcolm Dodson, Contract Analyst, who can be reached at Malcolm.dodson.ctr@health.mil.

A determination by the government not to compete this requirement based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.